Dural venous sinus stenting for idiopathic intracranial hypertension: An updated review - 29/03/19
pages | 7 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Background |
Dural venous sinus stenting (DVSS) is an accepted treatment option in selected patients with medically refractory idiopathic intracranial hypertension and obstructive venous outflow physiology prior to cerebrospinal flow diversion (CSFD) surgery. There are no randomized controlled studies focusing on outcomes and complication rates for dural venous sinus stenting.
Purpose |
We present the largest comprehensive meta-analysis on DVSS for idiopathic intracranial hypertension (IIH) focusing on success rates, complications, and re-stenting rates to date. We also present a simplified approach to direct retrograde internal jugular vein (IJ) access for DVSS that allows for expedited procedures.
Materials and methods |
We performed a retrospective electronic PubMed query of all peer-reviewed articles in the last 15 years between 2003 to 2018. We included all patients who underwent dural venous sinus stenting for a medically refractive IIH and excluded articles without sufficient data on outcomes, complication rates and re-stenting rates. We also evaluated and compared outcomes in patients undergoing direct retrograde IJ access DVSS to traditional transfemoral vein access.
Results |
A total of 29 papers and 410 patients who underwent DVSS met criteria for inclusion. DVSS was associated with high technical success [99.5%], low rates of repeated procedure [10%], and low major complication rates [1.5%].
Conclusion |
Our retrospective comprehensive review of DVSS for medically refractory IIH suggests that stenting in appropriately chosen patients is associated with low complication rates, high technical success, and low repeat procedure rates.
Le texte complet de cet article est disponible en PDF.Keywords : Idiopathic intracranial hypertension (IIH), Dural venous sinus stenting (DVSS), Internal jugular (IJ), Pseudotumor cerebri (PTC)
Plan
☆ | This paper was presented as a poster at the North American Neuro-Ophthalmology Society Annual meeting at Hawaii, Big Island, on March 6th 2018. |
Vol 46 - N° 2
P. 148-154 - mars 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?